Newsroom 2017

2017 Releases

17/10/2017
Australian Scientists awarded $2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease
Applications Open for CSL Centenary Fellowship Program Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance understanding of what really causes our arteries to clog.
 
More.

05/10/2017
New Debt Facilities
ASX Announcement

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 4 October 2017 it closed a new USD700 million private placement in the U.S. The private placement was foreshadowed in CSL’s full year announcement in August 2017.

More.

28/08/2017
CSL Behring Acquires Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
ASX Announcement

CSL Limited today announced that CSL Behring has agreed to acquire Calimmune, Inc., a US biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California, USA and Sydney, New South Wales, Australia for an upfront payment of $91 million.

More.

16/08/2017
Full Year Result 2017
Full Year Results CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $1,337 million for the 12 months ended 30 June 2017.
 
More.

03/08/2017
CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator
CSL Limited today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.
 
More.

10/07/2017
CSL Response to Patent Infringement Complaint
ASX Announcement

CSL Limited has become aware that Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the International Trade Commission.

More.

23/06/2017
HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) FDA Approval
ASX Announcement CSL today announced that the U.S. Food and Drug Administration (FDA) has approved CSL Behring’s HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
 
More.

13/06/2017
CSL to acquire majority stake in Chinese plasma fractionator
Wuhan Zhong Yuan Rui De Biologicals Products

ASX Announcement CSL to acquire an 80 per cent stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (“Ruide”) in China for US$352 million.
 
More.

01/06/2017
Applications Open for CSL Centenary Fellowship Program

$1.25 Million Funding Available to Australia’s Best and Brightest Biomedical Researchers


Applications Open for CSL Centenary Fellowship Program Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical research.
 
More.

12/04/2017
CSL Response to Patent Complaint
FY2017 profit upgrade CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims.
 
More.

15/02/2017
Half Year Result 20171
Half Year Results Announcement 2017 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP).
 
More.

10/02/2017
Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease
Study Published in Cell Metabolism

Melbourne, 10 February, 2017 04.00AM AEDT: An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes.

 
More.

19/01/2017
FY2017 profit upgrade
FY2017 profit upgrade CSL Limited (ASX:CSL; USOTC:CSLLY) today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance, CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016.
 
More.

05/01/2017
Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
Momenta

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017.

 
More.

© 2017 CSL Limited